846 filings
Page 4 of 43
8-K
ayeggevqm 77
28 Aug 23
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
8:00am
8-K
a7cluuj8ve
21 Aug 23
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
7:55am
8-K
u5ceofwma kbe98jjdp
14 Aug 23
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
8:00am
8-K
z9mahz
24 Jul 23
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
8:15am
8-K
100hnh2jkd3jvuokf
17 Jul 23
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral
8:15am
UPLOAD
z63qy90gq0n0xpe1du
5 Jul 23
Letter from SEC
12:00am
CORRESP
t4h09x6y
8 Jun 23
Correspondence with SEC
12:00am
8-K
slxg343x
7 Jun 23
Regulation FD Disclosure
8:00am
8-K
r6skx8a8
6 Jun 23
Regulation FD Disclosure
4:30pm
8-K
cnwfm
5 Jun 23
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
8:00am
8-K
q8ngnzmhvwfe3294lc
30 May 23
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
8:00am
8-K
y18ssfp
24 May 23
Termination of a Material Definitive Agreement
8:00am
8-K
rpf91ccl85w3ha8l
24 May 23
Regulation FD Disclosure
8:00am
8-K
odac ovdl2sj86vy0
22 May 23
Regulation FD Disclosure
8:00am
8-K
nv2x5jcom8tnyfq2
19 May 23
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
8:00am
8-K
zs7twbo367qadatgks
18 May 23
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
8:00am
UPLOAD
n6b0csbhd00l
15 May 23
Letter from SEC
12:00am